ATE382697T1 - Mutierte version der arginin deiminase - Google Patents
Mutierte version der arginin deiminaseInfo
- Publication number
- ATE382697T1 ATE382697T1 AT01932862T AT01932862T ATE382697T1 AT E382697 T1 ATE382697 T1 AT E382697T1 AT 01932862 T AT01932862 T AT 01932862T AT 01932862 T AT01932862 T AT 01932862T AT E382697 T1 ATE382697 T1 AT E382697T1
- Authority
- AT
- Austria
- Prior art keywords
- arginine deiminase
- present
- discloses
- mutated version
- methods
- Prior art date
Links
- 108010082340 Arginine deiminase Proteins 0.000 title abstract 4
- 150000001483 arginine derivatives Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108020004511 Recombinant DNA Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
- C12Y305/03006—Arginine deiminase (3.5.3.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Dairy Products (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/564,559 US6635462B1 (en) | 1997-05-12 | 2000-05-04 | Mutated form of arginine deiminase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE382697T1 true ATE382697T1 (de) | 2008-01-15 |
Family
ID=24254954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01932862T ATE382697T1 (de) | 2000-05-04 | 2001-05-02 | Mutierte version der arginin deiminase |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6635462B1 (de) |
| EP (1) | EP1278868B9 (de) |
| JP (1) | JP4709465B2 (de) |
| AT (1) | ATE382697T1 (de) |
| AU (1) | AU2001259353A1 (de) |
| CY (1) | CY1107351T1 (de) |
| DE (1) | DE60132190T2 (de) |
| DK (1) | DK1278868T3 (de) |
| ES (1) | ES2296750T3 (de) |
| PT (1) | PT1278868E (de) |
| WO (1) | WO2001083774A2 (de) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE505201T1 (de) * | 2002-02-14 | 2011-04-15 | Univ Leland Stanford Junior | Enzymbehandlung von nahrungsmitteln für zöliakie- sprue |
| US8143210B2 (en) | 2002-02-14 | 2012-03-27 | The Board Of Trustees Of The Leland Stanford Junior University | Enzyme treatment of foodstuffs for celiac sprue |
| CA2506244C (en) * | 2002-11-18 | 2012-10-30 | Phoenix Pharmacologics, Inc. | Methods for inhibiting viral replication in vivo |
| CA2502700C (en) | 2002-11-20 | 2017-01-17 | Chaitan Khosla | Diagnostic method for celiac sprue |
| US7579313B2 (en) * | 2003-11-18 | 2009-08-25 | The Board Of Trustees Of The Leland Stanford Junior University | Transglutaminase inhibitors and methods of use thereof |
| CN101002945B (zh) * | 2006-01-20 | 2012-09-05 | 清华大学 | 一种用于肿瘤治疗的新型复合物 |
| MX2009009780A (es) * | 2007-03-16 | 2010-05-20 | Univ Leland Stanford Junior | Terapia de enzima de combinacion para la digestion de gluten dietetico. |
| WO2008115428A2 (en) * | 2007-03-16 | 2008-09-25 | The Board Of Trustees Of The Leland Stanford Junior University | A scaleable manufacturing process for cysteine endoprotease b, isoform 2 |
| EP2295560A1 (de) | 2009-09-14 | 2011-03-16 | RWTH Aachen University | Zielgerichtete Evolution von Arginindeiminase zur erhöhten Aktivität im physiologischen pH |
| US9918881B2 (en) | 2011-11-22 | 2018-03-20 | Kimberly-Clark Worldwide, Inc. | Method of folding pant-like disposable absorbent garments in a trough |
| US10118754B2 (en) * | 2011-11-22 | 2018-11-06 | Kimberly-Clark Worldwide, Inc. | Method of folding pant-like disposable absorbent garments in a chute |
| US11123230B2 (en) * | 2011-11-22 | 2021-09-21 | Kimberly-Clark Worldwide, Inc. | Method of folding pant-like disposable absorbent garments in a chute |
| TW201611843A (en) | 2012-04-04 | 2016-04-01 | Polaris Group | Methods of treatment with arginine deiminase |
| EP3744341A1 (de) | 2013-03-15 | 2020-12-02 | TDW Group | Arginin-deiminase mit verminderter kreuzreaktivität gegenüber adi-peg-20-antikörpern zur krebsbehandlung |
| TWI676683B (zh) * | 2014-03-14 | 2019-11-11 | 開曼群島商瑞華藥業集團 | 用於癌症治療之對ａｄｉ－ｐｅｇ２０抗體交叉反應性降低之精胺酸去亞胺酶 |
| KR102523031B1 (ko) | 2014-03-18 | 2023-04-19 | 티디더블유 그룹 | 조작된 키메라성 페길화된 adi 및 사용 방법 |
| AU2015317848B2 (en) | 2014-09-16 | 2021-04-22 | Polaris Group | Arginine deiminase with reduced cross-reactivity toward ADI - PEG 20 antibodies for cancer treatment |
| CN104726478A (zh) * | 2015-03-09 | 2015-06-24 | 武汉远大弘元股份有限公司 | 表达精氨酸脱亚胺酶基因的重组大肠杆菌及其应用 |
| US10435682B2 (en) | 2016-02-19 | 2019-10-08 | University Of South Florida | Arginine deiminase gene therapy for disordered proteins |
| TWI847958B (zh) | 2016-07-05 | 2024-07-11 | 英屬開曼群島商北極星藥業集團股份有限公司 | 用精胺酸耗盡劑進行之組合癌症免疫療法 |
| EP3534963B1 (de) | 2016-11-02 | 2024-04-17 | Polaris Group | Formulierungen von pegylierter arginin-deiminase |
| CN108265044B (zh) * | 2016-12-31 | 2021-05-11 | 江苏众红生物工程创药研究院有限公司 | 聚乙二醇定点修饰的精氨酸脱亚胺酶及其制备方法与应用 |
| CN112442496B (zh) * | 2019-08-28 | 2023-05-12 | 江苏众红生物工程创药研究院有限公司 | 精氨酸脱亚胺酶突变体及其应用 |
| CN118792288B (zh) * | 2024-06-19 | 2025-03-04 | 中国医科大学附属第四医院 | 一种pH稳定性高的精氨酸脱亚胺酶突变体及其在肿瘤治疗中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| JP2900279B2 (ja) | 1989-08-02 | 1999-06-02 | 株式会社ジャパンエナジー | 新規なアルギニンデイミナーゼ、その製造法及び該酵素を有効成分とする制癌剤 |
| JP2736145B2 (ja) | 1990-01-11 | 1998-04-02 | 関東電化工業株式会社 | パーハロゲン化エチレンの製造法 |
| JP3209338B2 (ja) | 1990-09-10 | 2001-09-17 | 株式会社ジャパンエナジー | ポリエチレングリコール修飾アルギニンデイミナーゼおよびその製造法 |
| US5372942A (en) | 1992-02-10 | 1994-12-13 | Coriell Institute For Medical Research | Protease K resistant arginine deiminase, its method of preparation and its use as an anti-neoplastic agent |
| US5804183A (en) | 1997-01-31 | 1998-09-08 | Enzon, Inc. | Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same |
| EP1017794A1 (de) * | 1997-02-06 | 2000-07-12 | Novo Nordisk A/S | Polypeptid-polymer-konjugate mit hinzugefügten oder entfernten bindungsgruppen |
| US6183738B1 (en) | 1997-05-12 | 2001-02-06 | Phoenix Pharamacologics, Inc. | Modified arginine deiminase |
| US6180387B1 (en) | 1997-08-11 | 2001-01-30 | Smithkline Beecham Corporation | Arginine deiminase |
-
2000
- 2000-05-04 US US09/564,559 patent/US6635462B1/en not_active Expired - Lifetime
-
2001
- 2001-05-02 EP EP01932862A patent/EP1278868B9/de not_active Expired - Lifetime
- 2001-05-02 ES ES01932862T patent/ES2296750T3/es not_active Expired - Lifetime
- 2001-05-02 AU AU2001259353A patent/AU2001259353A1/en not_active Abandoned
- 2001-05-02 WO PCT/US2001/014116 patent/WO2001083774A2/en not_active Ceased
- 2001-05-02 AT AT01932862T patent/ATE382697T1/de active
- 2001-05-02 JP JP2001580381A patent/JP4709465B2/ja not_active Expired - Lifetime
- 2001-05-02 DK DK01932862T patent/DK1278868T3/da active
- 2001-05-02 DE DE60132190T patent/DE60132190T2/de not_active Expired - Lifetime
- 2001-05-02 PT PT01932862T patent/PT1278868E/pt unknown
-
2003
- 2003-08-21 US US10/645,723 patent/US20040258675A1/en not_active Abandoned
-
2008
- 2008-03-21 CY CY20081100327T patent/CY1107351T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1278868B9 (de) | 2008-10-29 |
| JP4709465B2 (ja) | 2011-06-22 |
| PT1278868E (pt) | 2008-04-11 |
| US6635462B1 (en) | 2003-10-21 |
| EP1278868A2 (de) | 2003-01-29 |
| DK1278868T3 (da) | 2008-05-19 |
| AU2001259353A1 (en) | 2001-11-12 |
| WO2001083774A2 (en) | 2001-11-08 |
| EP1278868B1 (de) | 2008-01-02 |
| DE60132190T2 (de) | 2008-12-11 |
| DE60132190D1 (de) | 2008-02-14 |
| US20040258675A1 (en) | 2004-12-23 |
| JP2003533186A (ja) | 2003-11-11 |
| CY1107351T1 (el) | 2012-12-19 |
| WO2001083774A3 (en) | 2002-05-23 |
| ES2296750T3 (es) | 2008-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE382697T1 (de) | Mutierte version der arginin deiminase | |
| HUP0002095A2 (hu) | Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk | |
| NO20013701D0 (no) | HER-2/neu-fusjonsproteiner | |
| AU2002305450A1 (en) | Proteomimetic compounds and methods | |
| DE60011100D1 (de) | Als cox-hemmer verwendbare sulfonylphenylpyrazol-verbindungen | |
| MXPA03006771A (es) | Anticuerpos modificados y metodos de uso. | |
| DK1368060T3 (da) | HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme | |
| EA200400648A1 (ru) | N, n'-замещенные производные 1,3-диамино-2-гидроксипропана | |
| MXPA03000627A (es) | Nuevos peptidos como inhibidores de proteasa serina-ns3 del virus de la hepatitis c. | |
| YU21399A (sh) | Konjugati koji sadrže delove rastvorljive u vodi, njihova upotreba u proizvodnji leka korisnog za tretiranje raka prostate i farmaceutske kompozicije koje ih sadrže | |
| ATE310089T1 (de) | Von dem syndrom der weissen flecken virus abgeleitete proteine und deren verwendungen | |
| MA27880A1 (fr) | Derives de tetrahydrocarbazole et leur utilisation pharmaceutique | |
| EP1536006A4 (de) | Krebsantigene und deren nutzung | |
| DE60037978D1 (de) | Interferon ähnliche moleküle, und deren verwendungen | |
| DE602004030541D1 (de) | Verfahren zur herstellung von alpha (2) makroglobulin-antigen-molekül-komplexen | |
| DE60129069D1 (de) | Hepatitis B Virus Vektoren für Gentherapie | |
| DE102005055128A1 (de) | Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor | |
| CO4920227A1 (es) | Histidina-n-bencil glicinamida sustituida con cicloalquilos . | |
| DE60229924D1 (de) | Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten | |
| FR2813606B1 (fr) | Proteine bard1 tronquee, et ses applications diagnostiques et therapeutiques | |
| ATE360062T1 (de) | Deglykosilierte fragmente der kringle 1-5 region von plasminogen und verwendungsverfahren | |
| DE60334289D1 (de) | Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen | |
| ATE459643T1 (de) | Ee3-proteinfamilie und zugrundeliegende dna- sequenzen | |
| NO20005321L (no) | Vertskodet protein uttrykt i Mareks sykdoms (MDV) infiserte celler og antistoffer til dette | |
| ATE210990T1 (de) | Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1278868 Country of ref document: EP |